# DOW Selects Battelle and CMC for ARDAP

The Department of War selected Battelle and CMC Pharmaceuticals for the five-year, $40 million Acetylcholinesterase Reactivator Development and Approval Pipeline (ARDAP) prototype program. The effort aims to advance an improved nerve-agent countermeasure toward an FDA investigational new drug application, creating demand for drug development, chemistry, manufacturing and controls, testing, and regulatory expertise. The article identifies no open solicitation or procurement contact; the award is market intelligence rather than a currently advertised bidding opportunity.

- The award signals federal demand for integrated medical-countermeasure capabilities spanning development, manufacturing controls, testing, and preparation for FDA review.
- Contractors with relevant expertise can use the award to identify capability areas and potential teaming needs in chemical and biological defense medical countermeasures.
- The 2026 Healthcare Summit is scheduled for December 3, 2026, and will cover federal health acquisition priorities; the article provides no registration or procurement contact details.

**Jurisdictions:** federal
**Industries:** Defense & Military, Healthcare
**Topics:** Regulatory Compliance
**Published:** October 19, 2026

### Government Entities
- Department of War (DOW)
- Defense Threat Reduction Agency (DTRA)
- Joint Science and Technology Office (JSTO)
- Food and Drug Administration (FDA)
- Department of the Army (Army)

### Vendors
- Battelle (ARDAP program awardee)
- CMC Pharmaceuticals (ARDAP program partner; chemistry, manufacturing and controls provider)
- SA-TECH (Prime contractor on the West Desert Test Center Mission Support Services contract)

### Key Quotes
> As the ARDAP program progresses toward IND submission, we are proud to continue supporting this important mission and to continue to drive next-generation solutions to emerging threats with a strong partner like CMC Pharmaceuticals.
> — Drew Cawthon, Business Line Director at Battelle

> We are excited to team with Battelle and provide our chemistry, manufacturing, and controls expertise to such an important program.
> — Mike Radomsky, President of CMC Pharmaceuticals

### Sources
- [DOW Selects Battelle, CMC for Medical Countermeasure Program](https://www.executivebiz.com/articles/dow-battelle-cmc-pharmaceuticals-ardap-prototype) - ExecutiveBiz